"Ki-1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. It is found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of the Ki-1 antigen in hematopoietic malignancies make it clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D017730
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.072 D23.050.285.025 D23.101.140.055
|
| Concept/Terms |
Ki-1 Antigen- Ki-1 Antigen
- Antigen, Ki-1
- Ki 1 Antigen
- CD30 Antigens
- Antigens, CD30
- Ber-H2 Antigen
- Antigen, Ber-H2
- Ber H2 Antigen
- TNFRSF8 Receptor
- Receptor, TNFRSF8
- Antigens, Ki-1
- Antigens, Ki 1
- Ki-1 Antigens
- Ki 1 Antigens
- Tumor Necrosis Factor Receptor Superfamily, Member 8
- CD30 Antigen
- Antigen, CD30
- Ber-H2 Antigens
- Antigens, Ber-H2
- Ber H2 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Ki-1 Antigen".
Below are MeSH descriptors whose meaning is more specific than "Ki-1 Antigen".
This graph shows the total number of publications written about "Ki-1 Antigen" by people in this website by year, and whether "Ki-1 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 3 | 3 | 6 |
| 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Ki-1 Antigen" by people in Profiles.
-
Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination. Leuk Lymphoma. 2021 10; 62(10):2554-2555.
-
Plasmablastic lymphoma of bone marrow: Report of a rare case and immunohistochemistry based approach to the diagnosis. Indian J Pathol Microbiol. 2019 Jan-Mar; 62(1):107-110.
-
Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. Blood Adv. 2018 12 11; 2(23):3479-3482.
-
Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP). Ann Hematol. 2018 Oct; 97(10):1817-1824.
-
Ethnic disparity in primary cutaneous CD30+ T-cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer Database. Br J Haematol. 2018 06; 181(6):752-759.
-
Influence of immunosuppressive drugs on the CD30 molecule in kidney transplanted patients. Hum Immunol. 2018 Jul; 79(7):550-557.
-
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018 Jun; 24 Suppl 2:S83-S94.
-
Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. PLoS Pathog. 2018 02; 14(2):e1006856.
-
Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder. J Hepatol. 2017 12; 67(6):1334-1339.
-
Serum sCD30: A promising biomarker for predicting the risk of bacterial infection after kidney transplantation. Transpl Infect Dis. 2017 Apr; 19(2).